Not available
Quote | Novartis AG (NYSE:NVS)
Last: | $94.36 |
---|---|
Change Percent: | -0.68% |
Open: | $93.2 |
Close: | $94.36 |
High: | $94.495 |
Low: | $93.15 |
Volume: | 2,338,261 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | Novartis AG (NYSE:NVS)
2024-04-19 14:48:33 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among ...
2024-04-19 11:02:48 ET Summary Novartis' Q1 outlook appears stable, with expectations of a rebound from a previous quarterly miss, projecting $11.57 billion in revenue. Key drugs like Fabhalta and Cosentyx may drive short-term growth, counteracting potential losses from generic co...
Message Board Posts | Novartis AG (NYSE:NVS)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $NVS News Article - Trading Novartis $NVS With Integrated Risk Controls | whytestocks | investorshangout | 03/10/2023 5:10:51 PM |
whytestocks: $NVS News Article - Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor | whytestocks | investorshangout | 12/09/2022 1:25:46 PM |
Former Head of Novartis Respiratory and Allergy Medicine | subslover | investorshub | 05/25/2022 1:21:42 PM |
https://www.novartis.com/news/media-releases/new-novartis-data-demonstrate-only- | FACT-MASTER | investorshub | 05/04/2022 10:57:17 PM |
https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approv | FACT-MASTER | investorshub | 05/04/2022 10:56:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Novartis AG Company Name:
NVS Stock Symbol:
NYSE Market:
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...
Novartis AG (NYSE:NVS) released data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta ...
2024-04-17 09:30:00 ET Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its shareholders by constantly raising its payouts -- and if it can do so for long...